"Stem Cells Dr. Nathan Newman" - Sean Wroe Jeuness Global Distributor
Stem Cells are the future of health and beauty. Jeunesse Global is at the forefront of this incredible Stem Cell Technology. Sean Wroe is a Jeunesse Global Distributor leading the way. http://www.seanwroe...
By: Sean Wroe
Originally posted here:
"Stem Cells Dr. Nathan Newman" - Sean Wroe Jeuness Global Distributor - Video
Scientists Find New Way To Make Human Platelets
Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Follow Follow Lauren Gores: http://www.twitter.com/laurengores...
By: NewsyVideos
Go here to see the original:
Scientists Find New Way To Make Human Platelets - Video
http://www.toothbank.com
Dental Stem Cell Banking. Secure your families future by storing your dental stem cells.
By: Jake Isenbarger
Go here to see the original:
http://www.toothbank.com - Video
A US Leader in Stem Cell Therapy - StemGenex
http://www.stemgenex.com/ - StemGenex offer patients access to cutting-edge adipose stem cell therapies for degenerative diseases, cosmetic enhancements and ...
By: EMSearch C
See the original post:
A US Leader in Stem Cell Therapy - StemGenex - Video
Los Angeles, CA (PRWEB) July 22, 2014
MetroMD, one of the leading names in regenerative medicines in all of California and one of the greatest proponents of holistic health services, now brings a reason to rejoice for individuals long suffering from debilitating arthritis. As per a report published on March 6 2013, by The Journal of Bone and Joint Surgery on The US National Library of Medicine National Institutes of Health (Ref: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748969/), on an average, around 500,000 revision of knee replacement surgeries were recorded in the US - with the prime reason being osteoarthritis in majority of these cases. And If Mr. Devin Stone, MetroMDs Operations Director is to be believed, the cumulative cost of the treatment is estimated to be around $50 billion every year.
The cost covers hospitals bills, doctors visits, medicine, etc and makes arthritic treatment, which often requires a repeat procedure, a hugely burdensome endeavor. But the fact is, even after spending so much of money, one is not sure about getting fully relieved from the agony that arthritis brings to ones life. Arthritis appears in many forms and the expresses itself as joint pain, stiffness and limited body movement in a patient, says Dr Alex Martin, MD, MetroMDs Director of Medicines. MetroMD, ensures that patients can put aside all these concerns and enjoy complete healing that only an advanced Stem cell therapy for arthritis can promise, says Dr. Martin highlighting the fact regarding how pocket-friendly the treatment is. One can regain a healthy knee, while retaining the health of his/her money bag now with MetroMDs stem cell therapy.
How does MetroMDs Stem cell therapy Work?
MetroMDs stem cell treatment process includes extraction of healthy bone marrow out of the patients body by experts and placing it in a centrifuge. After segregating various elements of blood, the stem cell is isolated and placed with cellular growth promoters (found in platelets). All of these are then inserted into the part of the body, ensuring a quicker tissue-based healing.
Mr. Devin Stone exuded confidence in mentioning that MetroMDs stem cell therapies come as a great alternative to invasive surgeries - making way for easier and quicker knee replacements and arthritic treatment.
Is the stem cell therapy safe?
Dr. Alex Martin says, If you are suffering from chronic joint paint due to arthritis, surgery is not anymore the only answer. Stem Cell Therapy can provide an amazing alternative, where your own cells are used to promote healing inside your body. Medicine has advanced significantly in the last 15 years and persistence with the techniques that were pioneered over two decades ago is illogical- and newer and less invasive procedures are the future of medicine.
Backed by the fact that stem cell treatment is a minimally invasive procedure requiring little or no hospitalization, Dr Martins and MetroMDs stance towards propagating stem cell therapy looks only logical. The procedure is legal and the therapy rendered by MetroMD is in compliance with CFR 21 part 1271 standards. Being a non surgical process, evidently, its the safest and totally side-effect free process.
Dr. Martin welcomes the residents of LA suffering from debilitating arthritic condition to consult an expert at its branches spread across in several parts of Los Angeles - and enjoy an improved quality of life.
Continue reading here:
Arthritis Alleviated: MetroMD Introduces Latest in Stem Cell Therapy in LA; Promises to be Especially Helpful for ...
Hello Doctor Nandani Gokulchandran On Stem Cell Therapy Treatment 20th July 2014
By: zee chovis taas
View post:
Hello Doctor Nandani Gokulchandran On Stem Cell Therapy Treatment 20th July 2014 - Video
ViaCyte, a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, has filed an Investigational New Drug application with the United States Food and Drug Administration, seeking to start a Phase 1/2 clinical trial in patients with type 1 diabetes, it was reported on Friday.
The trial will assess the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. The company has also submitted a Medical Device Master File to the United States Food and Drug Administration in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate. The company's VC-01 product candidate includes pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line.
Paul Laikind, Ph.D., president and chief executive officer of ViaCyte, said, 'The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials. The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organisation focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organisation for patients with type 1 diabetes.'
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Get our daily newsletter or follow us.
Please enter your email below:
The rest is here:
ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes
Published 18 July 2014
ViaCyte a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.
The trial would evaluate the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical Device Master File (called MAF) to the FDA in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate.
"The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials," said Paul Laikind, Ph.D., President and Chief Executive Officer of ViaCyte. "The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organization focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organization for patients with type 1 diabetes," added Dr. Laikind.
ViaCyte's VC-01 product candidate consists of pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line. These cells are then encapsulated by use of ViaCyte's Encaptra device. When implanted under the skin, the PEC-01 cells are designed to mature and further differentiate into insulin-producing beta and other endocrine cells that regulate blood glucose in a manner similar or identical to the normal islets that comprise the endocrine pancreas.
Based on a pre-IND meeting with the FDA and subsequent consultations, ViaCyte is proposing to initiate clinical evaluation of the VC-01 product candidate directly in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. In addition to evaluating the safety of the product candidate in these patients, the study is designed to demonstrate the effectiveness of the VC-01 product candidate in replacing lost endocrine function that is central to the disease.
In the proposed clinical trial, insulin production from the VC-01 implant would be assessed by measuring C-peptide, a biomarker for insulin produced by beta cells that is expected to provide a sensitive measure of efficacy in these patients. As proposed, the trial would also evaluate secondary end-points related to the need for administration of pharmaceutical insulin to control the disease and the incidence of hypoglycemia, a common side effect associated with pharmaceutical insulin usage.
ViaCyte's proprietary Encaptra device is designed to contain the implanted cells, preventing biodistribution, as well as shielding them from the immune system. Although PEC-01 cells are human cells, they are not the patient's actual cells. As such, they are considered an allogeneic graft, which typically requires immunosuppression in order for the recipient to tolerate the implant. However, the Encaptra device is designed to prevent the patient's immune system from accessing the implanted cells, thereby facilitating successful engraftment and subsequent maturation to islets.
The VC-01 product candidate is designed to be placed under the skin of the patient and can be monitored and readily removed, if or when required. The option to remove the cells is designed to provide an important safety benefit for this novel stem cell-derived cell therapy candidate. It is being regulated as a biologic through interaction with the Office of Cell, Tissue and Gene Therapy within CBER at the FDA. Given the combination product nature of the product candidate, the Center for Devices and Radiological Health at the FDA is also involved in its regulation.
The rest is here:
ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy ...
TRAGIC STORY! Paid $25,000 for Stem Cells @ Hospital Angeles Tijuana http://www.RegenerativeMedicine.mx
TWO Websites: http://www.regenerativemedicinemx.com AND http://www.regenerativemedicinetijuana.com STEM CELL Resources: http://www.cellmedicinesociety.org/component/content/article/86-news/410-mex...
By: KyaLarae
See the original post here:
TRAGIC STORY! Paid $25,000 for Stem Cells @ Hospital Angeles Tijuana http://www.RegenerativeMedicine.mx - Video
Stem Cell Therapy in Cardiac Disease - Charles Murry, MD, Ph.D.
How can we harness the power of stem cells to repair the heart or other damaged organs? Dr. Chuck Murry, Dept. of Pathology; Director, Center for Cardiovascular Biology at the University of...
By: UWTV
See the article here:
Stem Cell Therapy in Cardiac Disease - Charles Murry, MD, Ph.D. - Video
Common shoulder conditions treated with stem cell therapy
In this video, Ross Hauser, MD discusses the types of shoulder conditions our Prolotherapy team specializes in treating with stem cell therapy and platelet rich plasma Prolotherapy. If you...
By: Caring Medical and Rehabilitation Services
View original post here:
Common shoulder conditions treated with stem cell therapy - Video
Stem RX Bioscience Solution Pvt Ltd hold awareness program on stem cell therapy
By: nmtvindia
View original post here:
Stem RX Bioscience Solution Pvt Ltd hold awareness program on stem cell therapy - Video
Okyanos Heart Institute Live on 850 WFTL: Adult Stem Cell Therapy for Heart Disease
Okyanos #39; Chief Medical Officer Dr. Howard (Bo) Walpole and Chief Science Officer sat down with Karen Curtis at 850 WFTL in Ft. Lauderdale to discuss the promise of adult stem cell therapy as...
By: Okyanos Heart Institute
See the rest here:
Okyanos Heart Institute Live on 850 WFTL: Adult Stem Cell Therapy for Heart Disease - Video
Professor John Rasko on SBS Insight
Royal Prince Alfred Hospital #39;s Director of Cell and Molecular Therapies, Professor John Rasko, was invited as a guest on SBS Insight #39;s special on stem cell medicine.
By: SydneyLHD
Read more:
Professor John Rasko on SBS Insight - Video
There's no good time for a public agency to be embroiled in a conflict-of-interest scandal, but this is an especially delicate time for California's stem cell agency.
The California Institute for Regenerative Medicine, as the program is known formally, is on track to finish doling out its $3 billion in funding from the state's voters as soon as 2017. Its original sponsor, Northern California real estate developer Robert Klein II, has been quoted talking about another $5-billion infusion, perhaps via the 2016 ballot.
Any such effort will refocus attention on the program board's inherent conflicts of interest, which were baked in by the terms of Proposition 71, Klein's 2004 ballot initiative that created CIRM and funded it through a bond issue. The prestigious Institute of Medicine in a 2012 report found these conflicts to lead to questions about "the integrity and independence of some of CIRM's decisions."
And now here comes another case. This one involves CIRM former President Alan Trounson, an Australian biologist who left the agency on June 30 and joined the board of one of its highest-profile financial partners a mere seven days later. Trounson's new employer, Stem Cells Inc., is the recipient of a nearly $20-million loan for Alzheimer's research.
CIRM says Trounson's quick move to Stem Cells Inc., where he'll receive a stipend of at least $90,000 a year, is legally "permissible." But officials there acknowledge they were blindsided; the agency learned about Trounson's new position from the company's press release.
Afterward, CIRM rushed out a statement acknowledging that Trounson's appointment to the board of a CIRM loan recipient "creates a serious risk of a conflict of interest." The agency says it will place the relationship between CIRM and the company under "a full review." Administrators reminded Trounson, board members and agency staff that state law bars him from communicating with them on any administrative matter involving Stem Cells Inc. The company declined to comment.
The relationship already reeked of cronyism. As we reported in 2012, the Newark, Calif.-based firm's co-founder, Irving Weissman, director of Stanford University's Institute for Stem Cell Biology and Regenerative Medicine, had been one of the most prominent and outspoken supporters of Proposition 71.
He's also a leading recipient of CIRM funding, listed as the principal investigator on four Stanford grants totaling nearly $35 million. CIRM contributed $43.6 million toward the construction of his institute's $200-million research building at the Stanford campus. Weissman and his wife, Ann Tsukamoto, owned nearly 380,000 shares of the firm as of last April, according to a corporate disclosure. Tsukamoto is one of the company's top executives; Weissman is a board member.
Trounson's move comes as CIRM must begin looking to the future, but any discussions about extending the agency's life span will have to address the flaws created by Proposition 71. Among them is the program's very structure, and even its scientific goals.
Klein's ballot proposition exempts CIRM from virtually any oversight or accountability. Each of the 29 governing board members has to be associated with a California public or private research institution or company, or an advocacy group for patients of one disease or another. The qualifications for board chairman are so specific they initially yielded a single credible candidate: Bob Klein.
Read the rest here:
Conflicts of interest pervasive on California stem cell board
Insight: Stem Cells -- Kerri, Kristy and Jodi
Kerri Pottharst, Kristy Cruise and Jodi Russell reveal why they are choosing to have stem cell treatment to help with their illnesses. Catch the full episode...
By: Insight SBS
Visit link:
Insight: Stem Cells -- Kerri, Kristy and Jodi - Video
Before the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011
Name: XiaoYe Gender: Male Age: 4 years old Nationality: China Diagnosis: Cerebral Palsy XiaoYe, 4- year-old male, was diagnosed as Cerebral Palsy due to his retardation in both his motor and...
By: Stem Cells
Go here to see the original:
Before the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011 - Video
After the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011
Name: XiaoYe Gender: Male Age: 4 years old Nationality: China Diagnosis: Cerebral Palsy XiaoYe, 4- year-old male, was diagnosed as Cerebral Palsy due to his retardation in both his motor and...
By: Stem Cells
Go here to see the original:
After the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011 - Video
Before the fourth course of transplantation-Wu Yanyi - Cerebral Palsy (Male, 6 years old) 2008
Name: Wu Yanyi Gender: Male Age: 6 years old Nationality: China Diagnosis: Cerebral Palsy Wu Yanyi, Male, 6 years old, comes from Yingshan city in Hubei province. Preterm birth and was diagnosed...
By: Stem Cells
Read more from the original source:
Before the fourth course of transplantation-Wu Yanyi - Cerebral Palsy (Male, 6 years old) 2008 - Video
Before the first course of transplantation-Wu Yanyi - Cerebral Palsy (Male, 6 years old) 2008
Name: Wu Yanyi Gender: Male Age: 6 years old Nationality: China Diagnosis: Cerebral Palsy Wu Yanyi, Male, 6 years old, comes from Yingshan city in Hubei province. Preterm birth and was diagnosed...
By: Stem Cells